JPWO2020165776A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020165776A5 JPWO2020165776A5 JP2021547429A JP2021547429A JPWO2020165776A5 JP WO2020165776 A5 JPWO2020165776 A5 JP WO2020165776A5 JP 2021547429 A JP2021547429 A JP 2021547429A JP 2021547429 A JP2021547429 A JP 2021547429A JP WO2020165776 A5 JPWO2020165776 A5 JP WO2020165776A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- dimethyl
- triazol
- benzo
- methylphenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims 28
- 229910052739 hydrogen Inorganic materials 0.000 claims 18
- 239000001257 hydrogen Substances 0.000 claims 18
- 150000001875 compounds Chemical class 0.000 claims 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 11
- 239000000203 mixture Substances 0.000 claims 11
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 10
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 9
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 claims 9
- 235000019260 propionic acid Nutrition 0.000 claims 9
- 201000010099 disease Diseases 0.000 claims 8
- 125000000217 alkyl group Chemical group 0.000 claims 7
- -1 —CF 3 Chemical group 0.000 claims 6
- 206010019280 Heart failures Diseases 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 238000000634 powder X-ray diffraction Methods 0.000 claims 5
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 3
- 208000033626 Renal failure acute Diseases 0.000 claims 3
- 201000011040 acute kidney failure Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 125000001475 halogen functional group Chemical group 0.000 claims 3
- 150000002431 hydrogen Chemical group 0.000 claims 3
- KPPGHKCJHKBINH-FYYLOGMGSA-N (3R)-3-(1,4-dimethylbenzotriazol-5-yl)-3-[3-[[(2R)-2-ethyl-7-oxo-2,3,5,6-tetrahydropyrido[2,3-f][1,4]oxazepin-4-yl]methyl]-4-methylphenyl]propanoic acid Chemical compound C1=C(N=C2C(=C1)O[C@@H](CN(C2)CC1=C(C)C=CC(=C1)[C@@H](CC(=O)O)C1=CC=C2C(N=NN2C)=C1C)CC)O KPPGHKCJHKBINH-FYYLOGMGSA-N 0.000 claims 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000004990 Cardiorenal syndrome Diseases 0.000 claims 2
- 208000004051 Chronic Traumatic Encephalopathy Diseases 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 208000024412 Friedreich ataxia Diseases 0.000 claims 2
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 2
- 208000033051 Fuchs endothelial corneal dystrophy Diseases 0.000 claims 2
- 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 208000017004 dementia pugilistica Diseases 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 208000038002 heart failure with reduced ejection fraction Diseases 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 208000019423 liver disease Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 230000002685 pulmonary effect Effects 0.000 claims 2
- 230000001105 regulatory effect Effects 0.000 claims 2
- ADCAKSVOWWFFTI-JOCHJYFZSA-N (3R)-3-(1,4-dimethylbenzotriazol-5-yl)-3-[3-[(2,2-dimethyl-7-oxo-5,6-dihydro-3H-pyrido[2,3-f][1,4]oxazepin-4-yl)methyl]-4-methylphenyl]propanoic acid Chemical compound C1=C(N=C2C(=C1)OC(CN(C2)CC1=CC([C@@H](CC(=O)O)C2=CC=C3C(N=NN3C)=C2C)=CC=C1C)(C)C)O ADCAKSVOWWFFTI-JOCHJYFZSA-N 0.000 claims 1
- LHNVIJPKWMHEQN-WVXBCFDCSA-N (3R)-3-(1,4-dimethylbenzotriazol-5-yl)-3-[3-[[(2R)-2-ethyl-2-methyl-7-oxo-5,6-dihydro-3H-pyrido[2,3-f][1,4]oxazepin-4-yl]methyl]-4-methylphenyl]propanoic acid Chemical compound C1=C(N=C2C(=C1)O[C@@](CN(C2)CC1=CC([C@@H](CC(=O)O)C2=CC=C3C(N=NN3C)=C2C)=CC=C1C)(CC)C)O LHNVIJPKWMHEQN-WVXBCFDCSA-N 0.000 claims 1
- BOCFACJSLMDNFA-IFMALSPDSA-N (3R)-3-(1,4-dimethylbenzotriazol-5-yl)-3-[3-[[(2R)-2-ethyl-8-fluoro-7-oxo-2,3,5,6-tetrahydropyrido[2,3-f][1,4]oxazepin-4-yl]methyl]-4-methylphenyl]propanoic acid Chemical compound FC1=CC=2O[C@@H](CN(CC=2N=C1O)CC1=C(C)C=CC(=C1)[C@@H](CC(=O)O)C1=C(C=2N=NN(C=2C=C1)C)C)CC BOCFACJSLMDNFA-IFMALSPDSA-N 0.000 claims 1
- LHNVIJPKWMHEQN-DJUQAAIZSA-N (3R)-3-(1,4-dimethylbenzotriazol-5-yl)-3-[3-[[(2S)-2-ethyl-2-methyl-7-oxo-5,6-dihydro-3H-pyrido[2,3-f][1,4]oxazepin-4-yl]methyl]-4-methylphenyl]propanoic acid Chemical compound C1=C(N=C2C(=C1)O[C@](CN(C2)CC1=CC([C@@H](CC(=O)O)C2=CC=C3C(N=NN3C)=C2C)=CC=C1C)(CC)C)O LHNVIJPKWMHEQN-DJUQAAIZSA-N 0.000 claims 1
- KPPGHKCJHKBINH-JTHBVZDNSA-N (3R)-3-(1,4-dimethylbenzotriazol-5-yl)-3-[3-[[(2S)-2-ethyl-7-oxo-2,3,5,6-tetrahydropyrido[2,3-f][1,4]oxazepin-4-yl]methyl]-4-methylphenyl]propanoic acid Chemical compound CC[C@@H](CN(CC1=C(C)C=CC([C@@H](CC(O)=O)C(C=C2)=C(C)C3=C2N(C)N=N3)=C1)C1)OC(C=C2)=C1N=C2O KPPGHKCJHKBINH-JTHBVZDNSA-N 0.000 claims 1
- PPVWHFJBIRWLSQ-VGOFRKELSA-N (3R)-3-(1,4-dimethylbenzotriazol-5-yl)-3-[4-methyl-3-[[(2R)-2-methyl-7-oxo-2,3,5,6-tetrahydropyrido[2,3-f][1,4]oxazepin-4-yl]methyl]phenyl]propanoic acid Chemical compound C1=C(N=C2C(=C1)O[C@@H](CN(C2)CC1=CC([C@@H](CC(=O)O)C2=CC=C3C(N=NN3C)=C2C)=CC=C1C)C)O PPVWHFJBIRWLSQ-VGOFRKELSA-N 0.000 claims 1
- JDTOEIPTVKPRED-HYBUGGRVSA-N (3R)-3-(1,4-dimethylbenzotriazol-5-yl)-3-[4-methyl-3-[[(2R)-7-oxo-2-(trifluoromethyl)-2,3,5,6-tetrahydropyrido[2,3-f][1,4]oxazepin-4-yl]methyl]phenyl]propanoic acid Chemical compound C1=C(N=C2C(=C1)O[C@H](CN(C2)CC1=CC([C@@H](CC(=O)O)C2=C(C=3N=NN(C=3C=C2)C)C)=CC=C1C)C(F)(F)F)O JDTOEIPTVKPRED-HYBUGGRVSA-N 0.000 claims 1
- MMUHTTWXLZLRFU-KCWPFWIISA-N (3R)-3-(1,4-dimethylbenzotriazol-5-yl)-3-[4-methyl-3-[[(2R)-7-oxo-2-propan-2-yl-2,3,5,6-tetrahydropyrido[2,3-f][1,4]oxazepin-4-yl]methyl]phenyl]propanoic acid Chemical compound C1=C(N=C2C(O[C@@H](CN(C2)CC2=C(C)C=CC(=C2)[C@@H](CC(=O)O)C2=C(C=3N=NN(C=3C=C2)C)C)C(C)C)=C1)O MMUHTTWXLZLRFU-KCWPFWIISA-N 0.000 claims 1
- JDTOEIPTVKPRED-YKSBVNFPSA-N (3R)-3-(1,4-dimethylbenzotriazol-5-yl)-3-[4-methyl-3-[[(2S)-7-oxo-2-(trifluoromethyl)-2,3,5,6-tetrahydropyrido[2,3-f][1,4]oxazepin-4-yl]methyl]phenyl]propanoic acid Chemical compound C1=C(N=C2C(=C1)O[C@@H](CN(C2)CC1=CC([C@@H](CC(=O)O)C2=C(C=3N=NN(C=3C=C2)C)C)=CC=C1C)C(F)(F)F)O JDTOEIPTVKPRED-YKSBVNFPSA-N 0.000 claims 1
- MMUHTTWXLZLRFU-YIXXDRMTSA-N (3R)-3-(1,4-dimethylbenzotriazol-5-yl)-3-[4-methyl-3-[[(2S)-7-oxo-2-propan-2-yl-2,3,5,6-tetrahydropyrido[2,3-f][1,4]oxazepin-4-yl]methyl]phenyl]propanoic acid Chemical compound C1=C(N=C2C(=C1)O[C@H](CN(C2)CC1=C(C=CC([C@@H](CC(=O)O)C2=CC=C3C(N=NN3C)=C2C)=C1)C)C(C)C)O MMUHTTWXLZLRFU-YIXXDRMTSA-N 0.000 claims 1
- PGBBYGAVFZXMHU-KCWPFWIISA-N (3R)-3-[3-[[(2R)-2-tert-butyl-7-oxo-2,3,5,6-tetrahydropyrido[2,3-f][1,4]oxazepin-4-yl]methyl]-4-methylphenyl]-3-(1,4-dimethylbenzotriazol-5-yl)propanoic acid Chemical compound C1=C(N=C2C(O[C@@H](CN(C2)CC2=CC([C@@H](CC(=O)O)C3=CC=C4C(N=NN4C)=C3C)=CC=C2C)C(C)(C)C)=C1)O PGBBYGAVFZXMHU-KCWPFWIISA-N 0.000 claims 1
- UYNGWKVGTKVSFS-SANMLTNESA-N (3S)-3-(1,4-dimethylbenzotriazol-5-yl)-2,2-dimethyl-3-[4-methyl-3-[(7-oxo-2,3,5,6-tetrahydropyrido[2,3-f][1,4]oxazepin-4-yl)methyl]phenyl]propanoic acid Chemical compound C1=C(N=C2C(=C1)OCCN(C2)CC1=CC([C@@H](C2=C(C)C=3N=NN(C=3C=C2)C)C(C)(C)C(=O)O)=CC=C1C)O UYNGWKVGTKVSFS-SANMLTNESA-N 0.000 claims 1
- QJSAXJASXGJGLW-CLYVBNDRSA-N (3S)-3-(1,4-dimethylbenzotriazol-5-yl)-2,2-dimethyl-3-[4-methyl-3-[[(2R)-2-methyl-7-oxo-2,3,5,6-tetrahydropyrido[2,3-f][1,4]oxazepin-4-yl]methyl]phenyl]propanoic acid Chemical compound C1=CC=2O[C@@H](CN(CC=2N=C1O)CC1=C(C)C=CC([C@@H](C2=C(C)C=3N=NN(C=3C=C2)C)C(C)(C)C(=O)O)=C1)C QJSAXJASXGJGLW-CLYVBNDRSA-N 0.000 claims 1
- MPCCKSMQLIVAEI-RSXGOPAZSA-N (3S)-3-(1,4-dimethylbenzotriazol-5-yl)-2,2-dimethyl-3-[4-methyl-3-[[(2R)-7-oxo-2-(trifluoromethyl)-2,3,5,6-tetrahydropyrido[2,3-f][1,4]oxazepin-4-yl]methyl]phenyl]propanoic acid Chemical compound C1=C(N=C2C(=C1)O[C@H](CN(C2)CC1=C(C)C=CC(=C1)[C@H](C(C)(C)C(=O)O)C1=C(C)C=2N=NN(C=2C=C1)C)C(F)(F)F)O MPCCKSMQLIVAEI-RSXGOPAZSA-N 0.000 claims 1
- ARHXSRXMSHDRKX-YTMVLYRLSA-N (3S)-3-(1,4-dimethylbenzotriazol-5-yl)-2,2-dimethyl-3-[4-methyl-3-[[(2R)-7-oxo-2-propan-2-yl-2,3,5,6-tetrahydropyrido[2,3-f][1,4]oxazepin-4-yl]methyl]phenyl]propanoic acid Chemical compound C1=C(N=C2C(=C1)O[C@@H](CN(C2)CC1=CC([C@@H](C2=C(C)C=3N=NN(C=3C=C2)C)C(C)(C(=O)O)C)=CC=C1C)C(C)C)O ARHXSRXMSHDRKX-YTMVLYRLSA-N 0.000 claims 1
- QJSAXJASXGJGLW-MYUZEXMDSA-N (3S)-3-(1,4-dimethylbenzotriazol-5-yl)-2,2-dimethyl-3-[4-methyl-3-[[(2S)-2-methyl-7-oxo-2,3,5,6-tetrahydropyrido[2,3-f][1,4]oxazepin-4-yl]methyl]phenyl]propanoic acid Chemical compound C1=C(N=C2C(=C1)O[C@H](CN(C2)CC1=CC([C@@H](C2=C(C)C=3N=NN(C=3C=C2)C)C(C)(C)C(=O)O)=CC=C1C)C)O QJSAXJASXGJGLW-MYUZEXMDSA-N 0.000 claims 1
- MPCCKSMQLIVAEI-AHWVRZQESA-N (3S)-3-(1,4-dimethylbenzotriazol-5-yl)-2,2-dimethyl-3-[4-methyl-3-[[(2S)-7-oxo-2-(trifluoromethyl)-2,3,5,6-tetrahydropyrido[2,3-f][1,4]oxazepin-4-yl]methyl]phenyl]propanoic acid Chemical compound C1=C(N=C2C(=C1)O[C@@H](CN(C2)CC1=CC([C@@H](C2=C(C)C=3N=NN(C=3C=C2)C)C(C)(C(=O)O)C)=CC=C1C)C(F)(F)F)O MPCCKSMQLIVAEI-AHWVRZQESA-N 0.000 claims 1
- ARHXSRXMSHDRKX-PXJZQJOASA-N (3S)-3-(1,4-dimethylbenzotriazol-5-yl)-2,2-dimethyl-3-[4-methyl-3-[[(2S)-7-oxo-2-propan-2-yl-2,3,5,6-tetrahydropyrido[2,3-f][1,4]oxazepin-4-yl]methyl]phenyl]propanoic acid Chemical compound C1=C(N=C2C(=C1)O[C@H](CN(C2)CC1=CC([C@@H](C2=C(C)C=3N=NN(C=3C=C2)C)C(C)(C(=O)O)C)=CC=C1C)C(C)C)O ARHXSRXMSHDRKX-PXJZQJOASA-N 0.000 claims 1
- BIMZNDGETMODQW-MHZLTWQESA-N (3S)-3-(1,4-dimethylbenzotriazol-5-yl)-3-[3-[(2,2-dimethyl-7-oxo-5,6-dihydro-3H-pyrido[2,3-f][1,4]oxazepin-4-yl)methyl]-4-methylphenyl]-2,2-dimethylpropanoic acid Chemical compound C1=CC=2OC(C)(C)CN(CC=2N=C1O)CC1=C(C=CC(=C1)[C@H](C(C)(C)C(=O)O)C1=C(C)C=2N=NN(C=2C=C1)C)C BIMZNDGETMODQW-MHZLTWQESA-N 0.000 claims 1
- ADCAKSVOWWFFTI-QFIPXVFZSA-N (3S)-3-(1,4-dimethylbenzotriazol-5-yl)-3-[3-[(2,2-dimethyl-7-oxo-5,6-dihydro-3H-pyrido[2,3-f][1,4]oxazepin-4-yl)methyl]-4-methylphenyl]propanoic acid Chemical compound C1=C(N=C2C(=C1)OC(CN(C2)CC1=CC([C@@H](C2=C(C)C=3N=NN(C=3C=C2)C)CC(=O)O)=CC=C1C)(C)C)O ADCAKSVOWWFFTI-QFIPXVFZSA-N 0.000 claims 1
- OCKKECKRQFGNTF-DFHRPNOPSA-N (3S)-3-(1,4-dimethylbenzotriazol-5-yl)-3-[3-[[(2R)-2-ethyl-7-oxo-2,3,5,6-tetrahydropyrido[2,3-f][1,4]oxazepin-4-yl]methyl]-4-methylphenyl]-2,2-dimethylpropanoic acid Chemical compound CC[C@H](CN(CC1=C(C)C=CC([C@H](C(C)(C)C(O)=O)C(C=C2)=C(C)C3=C2N(C)N=N3)=C1)C1)OC(C=C2)=C1N=C2O OCKKECKRQFGNTF-DFHRPNOPSA-N 0.000 claims 1
- KPPGHKCJHKBINH-GGAORHGYSA-N (3S)-3-(1,4-dimethylbenzotriazol-5-yl)-3-[3-[[(2R)-2-ethyl-7-oxo-2,3,5,6-tetrahydropyrido[2,3-f][1,4]oxazepin-4-yl]methyl]-4-methylphenyl]propanoic acid Chemical compound CC[C@@H]1CN(CC2=C(O1)C=CC(=O)N2)CC3=C(C=CC(=C3)[C@H](CC(=O)O)C4=C(C5=C(C=C4)N(N=N5)C)C)C KPPGHKCJHKBINH-GGAORHGYSA-N 0.000 claims 1
- OCKKECKRQFGNTF-DWACAAAGSA-N (3S)-3-(1,4-dimethylbenzotriazol-5-yl)-3-[3-[[(2S)-2-ethyl-7-oxo-2,3,5,6-tetrahydropyrido[2,3-f][1,4]oxazepin-4-yl]methyl]-4-methylphenyl]-2,2-dimethylpropanoic acid Chemical compound C1=C(N=C2C(=C1)O[C@H](CN(C2)CC1=CC([C@@H](C2=C(C)C=3N=NN(C=3C=C2)C)C(C)(C(=O)O)C)=CC=C1C)CC)O OCKKECKRQFGNTF-DWACAAAGSA-N 0.000 claims 1
- KPPGHKCJHKBINH-GMAHTHKFSA-N (3S)-3-(1,4-dimethylbenzotriazol-5-yl)-3-[3-[[(2S)-2-ethyl-7-oxo-2,3,5,6-tetrahydropyrido[2,3-f][1,4]oxazepin-4-yl]methyl]-4-methylphenyl]propanoic acid Chemical compound C1=C(N=C2C(=C1)O[C@H](CN(C2)CC1=CC([C@@H](C2=C(C)C=3N=NN(C=3C=C2)C)CC(=O)O)=CC=C1C)CC)O KPPGHKCJHKBINH-GMAHTHKFSA-N 0.000 claims 1
- JDTOEIPTVKPRED-GBXCKJPGSA-N (3S)-3-(1,4-dimethylbenzotriazol-5-yl)-3-[4-methyl-3-[[(2R)-7-oxo-2-(trifluoromethyl)-2,3,5,6-tetrahydropyrido[2,3-f][1,4]oxazepin-4-yl]methyl]phenyl]propanoic acid Chemical compound C1=C(N=C2C(=C1)O[C@H](CN(C2)CC1=CC([C@@H](C2=C(C)C=3N=NN(C=3C=C2)C)CC(=O)O)=CC=C1C)C(F)(F)F)O JDTOEIPTVKPRED-GBXCKJPGSA-N 0.000 claims 1
- MMUHTTWXLZLRFU-HOFKKMOUSA-N (3S)-3-(1,4-dimethylbenzotriazol-5-yl)-3-[4-methyl-3-[[(2R)-7-oxo-2-propan-2-yl-2,3,5,6-tetrahydropyrido[2,3-f][1,4]oxazepin-4-yl]methyl]phenyl]propanoic acid Chemical compound C1=C(N=C2C(=C1)O[C@@H](CN(C2)CC1=CC([C@@H](C2=C(C)C=3N=NN(C=3C=C2)C)CC(=O)O)=CC=C1C)C(C)C)O MMUHTTWXLZLRFU-HOFKKMOUSA-N 0.000 claims 1
- JDTOEIPTVKPRED-RDPSFJRHSA-N (3S)-3-(1,4-dimethylbenzotriazol-5-yl)-3-[4-methyl-3-[[(2S)-7-oxo-2-(trifluoromethyl)-2,3,5,6-tetrahydropyrido[2,3-f][1,4]oxazepin-4-yl]methyl]phenyl]propanoic acid Chemical compound C1=C(N=C2C(=C1)O[C@@H](CN(C2)CC1=CC([C@@H](C2=C(C)C=3N=NN(C=3C=C2)C)CC(=O)O)=CC=C1C)C(F)(F)F)O JDTOEIPTVKPRED-RDPSFJRHSA-N 0.000 claims 1
- MMUHTTWXLZLRFU-WNCULLNHSA-N (3S)-3-(1,4-dimethylbenzotriazol-5-yl)-3-[4-methyl-3-[[(2S)-7-oxo-2-propan-2-yl-2,3,5,6-tetrahydropyrido[2,3-f][1,4]oxazepin-4-yl]methyl]phenyl]propanoic acid Chemical compound C1=C(N=C2C(=C1)O[C@H](CN(C2)CC1=CC([C@@H](C2=C(C)C=3N=NN(C=3C=C2)C)CC(=O)O)=CC=C1C)C(C)C)O MMUHTTWXLZLRFU-WNCULLNHSA-N 0.000 claims 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 208000032781 Diabetic cardiomyopathy Diseases 0.000 claims 1
- 208000020564 Eye injury Diseases 0.000 claims 1
- 208000003736 Gerstmann-Straussler-Scheinker Disease Diseases 0.000 claims 1
- 206010072075 Gerstmann-Straussler-Scheinker syndrome Diseases 0.000 claims 1
- 206010019799 Hepatitis viral Diseases 0.000 claims 1
- 208000025500 Hutchinson-Gilford progeria syndrome Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010062016 Immunosuppression Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000032382 Ischaemic stroke Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 1
- 208000014060 Niemann-Pick disease Diseases 0.000 claims 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 1
- 102000029797 Prion Human genes 0.000 claims 1
- 108091000054 Prion Proteins 0.000 claims 1
- 208000024777 Prion disease Diseases 0.000 claims 1
- 208000007932 Progeria Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims 1
- 201000004224 Schnyder corneal dystrophy Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000034799 Tauopathies Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 208000024716 acute asthma Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 claims 1
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 claims 1
- 229940024142 alpha 1-antitrypsin Drugs 0.000 claims 1
- 208000008445 altitude sickness Diseases 0.000 claims 1
- 206010002022 amyloidosis Diseases 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 208000023819 chronic asthma Diseases 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 238000002447 crystallographic data Methods 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 201000006061 fatal familial insomnia Diseases 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 208000038003 heart failure with preserved ejection fraction Diseases 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 230000001506 immunosuppresive effect Effects 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000002107 myocardial effect Effects 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 229960005489 paracetamol Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 201000011461 pre-eclampsia Diseases 0.000 claims 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 238000007634 remodeling Methods 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 108700012359 toxins Proteins 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
- 201000001862 viral hepatitis Diseases 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962806201P | 2019-02-15 | 2019-02-15 | |
| US62/806,201 | 2019-02-15 | ||
| US201962931877P | 2019-11-07 | 2019-11-07 | |
| US62/931,877 | 2019-11-07 | ||
| PCT/IB2020/051100 WO2020165776A1 (en) | 2019-02-15 | 2020-02-11 | Hydroxypyridoxazepines as nrf2 activators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022520442A JP2022520442A (ja) | 2022-03-30 |
| JPWO2020165776A5 true JPWO2020165776A5 (enExample) | 2023-02-21 |
| JP7602469B2 JP7602469B2 (ja) | 2024-12-18 |
Family
ID=69726636
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021547429A Active JP7602469B2 (ja) | 2019-02-15 | 2020-02-11 | Ｎｒｆ２活性剤としてのヒドロキシピリドキシアゼピン |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US11945826B2 (enExample) |
| EP (1) | EP3924356A1 (enExample) |
| JP (1) | JP7602469B2 (enExample) |
| KR (1) | KR102932313B1 (enExample) |
| CN (2) | CN113474349B (enExample) |
| AU (1) | AU2020222080C1 (enExample) |
| BR (1) | BR112021016042A2 (enExample) |
| CA (1) | CA3129955A1 (enExample) |
| CL (1) | CL2021002110A1 (enExample) |
| CO (1) | CO2021010930A2 (enExample) |
| IL (2) | IL313950A (enExample) |
| MA (1) | MA54939A (enExample) |
| MX (1) | MX2021009659A (enExample) |
| MY (1) | MY209603A (enExample) |
| PH (1) | PH12021551873A1 (enExample) |
| SG (1) | SG11202108257TA (enExample) |
| TW (2) | TWI880702B (enExample) |
| WO (1) | WO2020165776A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021002060A (es) | 2018-08-20 | 2021-07-21 | Janssen Pharmaceutica Nv | Inhibidores de la interacción proteína-proteína keap1-nrf2. |
| AR118050A1 (es) | 2019-02-15 | 2021-09-15 | Bristol Myers Squibb Co | Compuestos bicíclicos sustituidos como moduladores del receptor farnesoide x |
| CN113474349B (zh) * | 2019-02-15 | 2024-03-01 | 葛兰素史密斯克莱知识产权发展有限公司 | 作为nrf2活化剂的羟基吡啶并氧氮杂环庚三烯 |
| BR112021023927A2 (pt) * | 2019-05-31 | 2022-02-08 | Ube Industries | Composto, e, composição farmacêutica |
| CR20240325A (es) * | 2022-01-07 | 2024-11-22 | Chugai Pharmaceutical Co Ltd | Compuesto heterocíclico que contiene nitrógeno que tiene un efecto de activación del nrf2 |
| WO2023210741A1 (ja) | 2022-04-28 | 2023-11-02 | 第一三共株式会社 | ベンゾトリアゾール化合物 |
| US20250296939A1 (en) * | 2022-04-28 | 2025-09-25 | Kyoto Pharmaceutical Industries, Ltd. | Benzothiophene compound |
| US20260053777A1 (en) * | 2022-09-02 | 2026-02-26 | Institut National de la Santé et de la Recherche Médicale | Use of nrf2 activators for the treatment of cerebral small vessel disease |
| WO2024262491A1 (ja) * | 2023-06-19 | 2024-12-26 | 中外製薬株式会社 | Ｎｒｆ２活性化作用を有する含窒素複素環化合物の結晶 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2670099A1 (en) * | 2006-11-17 | 2008-05-29 | Trustees Of Dartmouth College | Synthesis and biological activities of new tricyclic-bis-enones (tbes) |
| US9056850B2 (en) * | 2008-10-17 | 2015-06-16 | Janssen Pharmaceutica N.V. | Process for the preparation of compounds useful as inhibitors of SGLT |
| CN104418834B (zh) * | 2013-08-23 | 2017-09-15 | 重庆博腾制药科技股份有限公司 | 一种抗糖尿病药物中间体的合成方法 |
| AU2014369153B2 (en) | 2013-12-18 | 2017-09-21 | Astex Therapeutics Limited | Nrf2 regulators |
| CN105272960A (zh) * | 2014-07-18 | 2016-01-27 | 上海科胜药物研发有限公司 | 一种坎格列净中间体2-(2-甲基-5-溴苄基)-5-(4-氟苯)噻吩的制备方法 |
| US10556877B2 (en) * | 2015-05-05 | 2020-02-11 | Glenmark Life Sciences Limited | Process for preparation of dapagliflozin |
| CN108137557B (zh) | 2015-06-15 | 2021-09-07 | 葛兰素史密斯克莱知识产权发展有限公司 | Nrf2调节剂 |
| CA2988338C (en) | 2015-06-15 | 2024-05-14 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 regulators |
| JP2018517732A (ja) | 2015-06-15 | 2018-07-05 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Ｎｒｆ２レギュレーター |
| US10201531B2 (en) * | 2015-08-12 | 2019-02-12 | Mochida Pharmaceutical Co., Ltd. | Indazolyl-oxo-isothiazole compounds |
| WO2017060854A1 (en) * | 2015-10-06 | 2017-04-13 | Glaxosmithkline Intellectual Property Development Limited | Biaryl pyrazoles as nrf2 regulators |
| US10913762B2 (en) * | 2016-01-27 | 2021-02-09 | Msn Laboratories Private Limited | Process for the preparation of D-glucitol, 1,5-anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl] oxy]phenyl] methyl] phenyl]-, (1S) and its crystalline forms thereof |
| WO2018104766A1 (en) * | 2016-12-06 | 2018-06-14 | Glaxosmithkline Intellectual Property Development Limited | 3-(2,3-dihydro-1h-inden-5-yl)propanoic acid derivatives and their use as nrf2 regulators |
| WO2018109642A1 (en) * | 2016-12-12 | 2018-06-21 | Glaxosmithkline Intellectual Property Development Limited | N-aryl pyrazoles as nrf2 regulators |
| ES2901617T3 (es) * | 2016-12-14 | 2022-03-23 | Glaxosmithkline Ip Dev Ltd | Bisarilamidas como reguladores de NRF2 |
| AU2017376900A1 (en) | 2016-12-15 | 2019-05-23 | Glaxosmithkline Intellectual Property Development Limited | NRF2 compounds |
| CN113474349B (zh) * | 2019-02-15 | 2024-03-01 | 葛兰素史密斯克莱知识产权发展有限公司 | 作为nrf2活化剂的羟基吡啶并氧氮杂环庚三烯 |
-
2020
- 2020-02-11 CN CN202080014726.4A patent/CN113474349B/zh active Active
- 2020-02-11 JP JP2021547429A patent/JP7602469B2/ja active Active
- 2020-02-11 PH PH1/2021/551873A patent/PH12021551873A1/en unknown
- 2020-02-11 WO PCT/IB2020/051100 patent/WO2020165776A1/en not_active Ceased
- 2020-02-11 CA CA3129955A patent/CA3129955A1/en active Pending
- 2020-02-11 SG SG11202108257TA patent/SG11202108257TA/en unknown
- 2020-02-11 IL IL313950A patent/IL313950A/en unknown
- 2020-02-11 US US17/429,088 patent/US11945826B2/en active Active
- 2020-02-11 MX MX2021009659A patent/MX2021009659A/es unknown
- 2020-02-11 EP EP20708180.3A patent/EP3924356A1/en active Pending
- 2020-02-11 MA MA054939A patent/MA54939A/fr unknown
- 2020-02-11 KR KR1020217029193A patent/KR102932313B1/ko active Active
- 2020-02-11 BR BR112021016042-6A patent/BR112021016042A2/pt unknown
- 2020-02-11 CN CN202410206971.5A patent/CN118206566A/zh active Pending
- 2020-02-11 AU AU2020222080A patent/AU2020222080C1/en active Active
- 2020-02-11 MY MYPI2021004562A patent/MY209603A/en unknown
- 2020-02-11 IL IL285438A patent/IL285438B2/en unknown
- 2020-02-13 TW TW113112455A patent/TWI880702B/zh active
- 2020-02-13 TW TW109104455A patent/TWI843806B/zh active
-
2021
- 2021-08-11 CL CL2021002110A patent/CL2021002110A1/es unknown
- 2021-08-19 CO CONC2021/0010930A patent/CO2021010930A2/es unknown
-
2024
- 2024-02-27 US US18/588,051 patent/US20240352034A1/en not_active Abandoned
-
2025
- 2025-02-14 US US19/054,254 patent/US20250313573A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5373634B2 (ja) | ムスカリンｍ３アンタゴニストのナパジシル酸塩 | |
| CN104837828B (zh) | 作为pde4‑抑制剂的苯基乙基吡啶衍生物 | |
| JP2018529745A5 (enExample) | ||
| JPH07505648A (ja) | アザサイクリック化合物 | |
| JPWO2020165776A5 (enExample) | ||
| JP2018517731A5 (enExample) | ||
| EP2225205A1 (en) | Ester derivatives as phosphodiesterase inhibitors | |
| JPWO2015079692A1 (ja) | ウレア誘導体、またはその薬理学的に許容される塩 | |
| TW202045514A (zh) | 作為ｎｒｆ２活化劑之羥基吡啶并氧氮呯 | |
| EP3508483B1 (en) | Dihydropyrimidine compound and preparation method and use thereof | |
| EP4132908A1 (en) | Indole derivatives as alpha-1 -antitrypsin modulators for treating alpha-1 -antitrypsin deficiency (aatd) | |
| WO1996010024A1 (fr) | Derive pyrimidinylpyrazole | |
| WO2022007772A1 (zh) | 取代苯并咪唑类衍生物及其应用 | |
| JP5476372B2 (ja) | ２−オキソ−アルキル−１−ピペラジン−２−オンの誘導体、これらの調製方法およびこれらの治療的使用 | |
| CN105814034A (zh) | 用于治疗呼吸病的二苯甲基衍生物 | |
| JP2024508378A (ja) | ジフェニルピラジン誘導体の製造プロセス | |
| CN111148742A (zh) | 芳香族化合物及其药物组合物和用途 | |
| JP5052497B2 (ja) | ヒスタミンｈ３受容体アンタゴニストとしてのピロリジン誘導体 | |
| RU2024102364A (ru) | Гидроксипиридоксазепины в качестве активаторов nrf2 | |
| RU2021126939A (ru) | Гидроксипиридоксазепины в качестве активаторов nrf2 | |
| AU2020320034A1 (en) | Inhibitors of human ATGL | |
| CN111936488A (zh) | 用于治疗寄生虫感染的新颖化合物 | |
| EP2114875B1 (en) | Substituted arylcylopentenes as therapeutic agents | |
| CN1379776A (zh) | 包含噻唑烷二酮衍生物的药物组合物及其制备方法 | |
| JPH10279567A (ja) | トリアゾール誘導体 |